Poulton Named as Alnylam Pharmaceuticals Chief Financial Officer
15 July 2019 - - Jeff Poulton is joining US-based RNAi therapeutics company Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) and has been appointed executive vice president and chief financial officer, effective August 13, 2019, the company said.
He will join Alnylam with nearly 25 years of financial, operational and strategic leadership experience, including serving as executive vice president and CFO of Shire plc.
Manmeet S. Soni has decided to resign to pursue other interests; he will continue as CFO of Alnylam through August 12, 2019 providing a smooth transition.
Poulton was most recently chief financial officer of Indigo Ag, Inc., a company dedicated to harnessing nature to help farmers sustainably feed the planet. Prior to that Poulton was chief financial officer of Shire plc, and member of Shire's Executive Committee and board of directors.
As CFO of Shire, he had responsibility for all aspects of the finance organization including SEC reporting, Treasury, Tax, Internal Audit, Financial Planning and Analysis, Investor Relations, and Procurement.
Prior to his CFO role at Shire he held a variety of financial roles and also served in a general management capacity while leading Shire's rare disease commercial operations in North America, Latin America, and Asia Pacific.
Before his fifteen-year tenure at Shire, Poulton led corporate finance and business development initiatives in both the energy and materials manufacturing sectors, in financial leadership positions at Cinergy Corp and PPG industries. He also served as a US Navy Commissioned officer.